ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2026 · 108 positions · Total reported value $4.84B · Top-10 concentration 44.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2026 13F filing, ORBIMED ADVISORS LLC disclosed 108 equity positions with a combined reported value of $4.84B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 44.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were EWTX ($488.83M), ELVN ($312.01M), MDXH ($285.90M). By sector, the heaviest allocations are Health Care 92.3%, Industrials 1.8%. Versus the prior quarter, allocation shifted toward Health Care (+8.8pp) and away from Industrials (-1.7pp), Other (-7.1pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 64% of names.

The largest new positions opened in Q1 2026 were MDXH ($285.90M), AZN ($132.18M), MYGN ($122.88M).

Of the 23 positions fully exited versus the prior quarter, the largest were TERN ($86.99M), APLS ($61.04M), CI ($56.42M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • MDXH MDXHEALTH SA · $285.90M
  • AZN ASTRAZENECA PLC · $132.18M
  • MYGN MYRIAD GENETICS INC COM · $122.88M
  • MRK MERCK & CO INC · $79.80M
  • RCEL AVITA MEDICAL INC · $42.52M
  • GH GUARDANT HEALTH INC · $40.20M
  • SNDX SYNDAX PHARMACEUTICALS INC COM · $22.48M
  • STRO SUTRO BIOPHARMA INC · $19.96M

Fully Exited (vs previous quarter)

  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $86.99M
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $61.04M
  • CI THE CIGNA GROUP · prev qtr: $56.42M
  • RAPT RAPT THERAPEUTICS INC · prev qtr: $55.64M
  • UTHR UNITED THERAPEUTICS CORP DEL · prev qtr: $51.26M
  • ROIV ROIVANT SCIENCES LTD SHS · prev qtr: $47.54M
  • RNAM AVIDITY BIOSCIENCES INC · prev qtr: $44.69M
  • NBIX NEUROCRINE BIOSCIENCES INC · prev qtr: $44.57M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 92.3%
Other 5.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.52M $488.83M 10.10%
10.10%
Hold
2 7.96M $312.01M 6.45%
6.45%
Hold
3 124.31M $285.90M 5.91%
5.91%
New
4 236.80K $217.80M 4.50%
4.50%
Reduce
5 2.72M $184.47M 3.81%
3.81%
Hold
6 2.38M $149.48M 3.09%
3.09%
Reduce
7 3.53M $141.55M 2.92%
2.92%
Reduce
8 670.20K $132.18M 2.73%
2.73%
New
9 125.00M $122.88M 2.54%
2.54%
New
10 3.64M $108.59M 2.24%
2.24%
Reduce
11 7.17M $104.82M 2.17%
2.17%
Hold
12 136.90K $99.97M 2.07%
2.07%
Reduce
13 1.23M $98.55M 2.04%
2.04%
Add
14 208.70K $96.21M 1.99%
1.99%
Reduce
15 15.22M $80.51M 1.66%
1.66%
Hold
16 663.40K $79.80M 1.65%
1.65%
New
17 1.48M $71.11M 1.47%
1.47%
Add
18 3.03M $69.84M 1.44%
1.44%
Hold
19 1.07M $68.26M 1.41%
1.41%
Hold
20 8.29M $66.56M 1.38%
1.38%
Hold
21 948.27K $64.18M 1.33%
1.33%
Reduce
22 1.06M $61.64M 1.27%
1.27%
Add
23 182.50K $59.97M 1.24%
1.24%
Reduce
24 925.00K $56.10M 1.16%
1.16%
Add
25 2.05M $55.61M 1.15%
1.15%
Add
26 172.50K $55.58M 1.15%
1.15%
Add
27 1.95M $54.66M 1.13%
1.13%
Add
28 2.92M $52.90M 1.09%
1.09%
Add
29 262.00K $52.40M 1.08%
1.08%
Reduce
30 465.70K $51.86M 1.07%
1.07%
Add
31 5.69M $51.24M 1.06%
1.06%
Hold
32 265.80K $50.40M 1.04%
1.04%
Reduce
33 2.81M $50.19M 1.04%
1.04%
Reduce
34 41.04M $42.52M 0.88%
0.88%
New
35 181.98K $41.62M 0.86%
0.86%
Add
36 6.31M $40.55M 0.84%
0.84%
Hold
37 435.20K $40.20M 0.83%
0.83%
New
38 119.00K $39.37M 0.81%
0.81%
Reduce
39 10.91M $37.31M 0.77%
0.77%
Hold
40 999.00K $36.28M 0.75%
0.75%
Hold
41 213.92K $36.16M 0.75%
0.75%
Reduce
42 2.14M $34.93M 0.72%
0.72%
Add
43 2.69M $34.13M 0.70%
0.70%
Reduce
44 114.70K $33.58M 0.69%
0.69%
Add
45 4.72M $32.82M 0.68%
0.68%
Add
46 1.20M $31.00M 0.64%
0.64%
Hold
47 2.45M $29.28M 0.60%
0.60%
Reduce
48 10.57M $28.96M 0.60%
0.60%
Add
49 2.10M $27.57M 0.57%
0.57%
Reduce
50 314.10K $27.32M 0.56%
0.56%
Add

FAQ

What did ORBIMED ADVISORS LLC buy in 2026-Q1?

In its 2026-Q1 13F filing, ORBIMED ADVISORS LLC reported 108 equity positions worth $4.84B in aggregate; its largest disclosed positions were EWTX ($488.83M), ELVN ($312.01M), MDXH ($285.90M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.84B of long equity holdings across 108 positions as of 2026-Q1. Top-10 holdings account for 44.3% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →